CASCADE试验8年随访:冠脉搭桥术后第一年加用氯吡格雷的长期结局
CASCADE试验8年随访评估冠脉搭桥术后第一年阿司匹林加氯吡格雷与阿司匹林加安慰剂相比的长期结局。共113例患者随机分组,中位随访7.6年,两组生存率无显著差异,但阿司匹林-氯吡格雷组自体冠状动脉中重度病变进展发生率更低(P=.02),主要不良心脑血管事件或死亡无事件生存有改善趋势(P=.11)。
要点
- 冠脉搭桥术后第一年加用氯吡格雷未显著改善8年生存率。
- 加用氯吡格雷组自体冠状动脉中重度病变进展发生率显著更低。
- 主要不良心脑血管事件或死亡无事件生存有改善趋势但未达统计学显著。
核心结论
- 冠脉搭桥术后第一年加用氯吡格雷与更低的自体冠状动脉中重度病变进展发生率相关。
- 阿司匹林-氯吡格雷组主要不良心脑血管事件(含血运重建)或死亡无事件生存有改善趋势。
研究设计与样本
- CASCADE试验为双盲随机对照试验,113例冠脉搭桥术后患者随机接受每日氯吡格雷(n=56)或安慰剂(n=57)联合阿司匹林治疗1年。
- 8年随访收集长期临床数据,肾小球滤过率>30 mL/min的存活患者接受冠状动脉CT血管造影评估晚期大隐静脉桥血管通畅性和自体冠状动脉病变进展。
主要发现
- 中位随访7.6年,生存率为85.5%±3.8%(两组间P=.23)。
- 阿司匹林-氯吡格雷组全因死亡或主要不良心脑血管事件(含血运重建)无事件生存有改善趋势(P=.11)。
- 两组功能状态或无 angina 生存无差异(P>.57)。
- 大隐静脉桥血管长期通畅率阿司匹林-氯吡格雷组为89.11%,阿司匹林-安慰剂组为91.23%(P=.79)。
- 阿司匹林-氯吡格雷组自体冠状动脉中重度病变进展发生率更低:进展段分别为122段中7段 vs 78段中13段(比值比0.3±0.2;95%置信区间0.1-0.8;P=.02)。
关键数值与推荐
- 冠脉搭桥术后第一年每日氯吡格雷联合阿司匹林,与阿司匹林联合安慰剂相比,8年随访时自体冠状动脉中重度病变进展比值比为0.3±0.2(95%置信区间0.1-0.8;P=.02)。
- 大隐静脉桥血管长期通畅率两组分别为89.11%和91.23%(P=.79)。
- 中位随访7.6年生存率85.5%±3.8%(两组间P=.23)。
临床怎么用
- 冠脉搭桥术后第一年加用氯吡格雷可能减缓自体冠状动脉病变进展,但需权衡长期获益与出血风险。
- 该策略未显著改善8年生存率,主要不良心脑血管事件无事件生存仅有改善趋势。
- 大隐静脉桥血管长期通畅性未见显著获益,临床决策应个体化。
局限性
- 8年随访时部分患者失访或未完成冠状动脉CT血管造影,可能影响结果解释。
- 自体冠状动脉病变进展分析基于可评估的冠状动脉段而非全部患者,存在选择偏倚可能。
- 主要不良心脑血管事件或死亡无事件生存的组间比较未达统计学显著(P=.11),结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In this 8 years' follow-up study, we evaluated the long-term outcomes of the addition of clopidogrel to aspirin during the first year after coronary artery bypass grafting, versus aspirin plus placebo, with respect to survival, major adverse cardiac, or major cerebrovascular events, including revascularization, functional status, graft patency, and native coronary artery disease progression. METHODS: In the initial Clopidogrel After Surgery for Coronary Artery Disease trial, 113 patients were randomized to receive either daily clopidogrel (n = 56) or placebo (n = 57), in addition to aspirin, in a double-blind fashion for 1 year after coronary artery bypass grafting. All patients were re-evaluated to collect long-term clinical data. Surviving patients with a glomerular filtration rate > 30 mL/min were asked to undergo a coronary computed tomography angiogram to evaluate the late saphenous vein graft patency and native coronary artery disease progression. RESULTS: At a median follow-up of 7.6 years, survival rate was 85.5% ± 3.8% (P = .23 between the 2 groups). A trend toward enhanced freedom from all-cause death or major adverse cardiac or cerebrovascular events, including revascularization, was observed in the aspirin-clopidogrel group (P = .11). No difference in functional status or freedom from angina was observed between the 2 groups (P > .57). The long-term patency of saphenous vein graft was 89.11% in the aspirin-clopidogrel group versus 91.23% in the aspirin-placebo group (P = .79). A lower incidence of moderate to severe native disease progression was observed in the aspirin-clopidogrel group versus the aspirin-placebo group (7 out of 122 vs 13 out of 78 coronary segments that showed progression, respectively [odds ratio, 0.3 ± 0.2; 95% confidence interval, 0.1-0.8; P = .02]). CONCLUSIONS: At 8 years' follow-up, the addition of clopidogrel to aspirin during the first year after coronary artery bypass grafting exhibited a lower incidence of moderate to severe progression of native coronary artery disease and a trend toward higher freedom from major adverse cardiac or cerebrovascular events, including revascularization, or death in the aspirin-clopidogrel group. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT00228423.
引用
- Hage A, Voisine P, Erthal F, et al. Eight-year follow-up of the Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) trial. J Thorac Cardiovasc Surg. 2017. PMID: 28734623. doi:10.1016/j.jtcvs.2017.06.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。